
Lotteries commission looks set to plug funding gap after US aid cuts to SA HIV programmes
The National Lotteries Commission and the private sector look set to fill the funding gap in the health sector, particularly for HIV and TB programmes.
This comes after US President Donald Trump cut funding to South Africa's health programmes.
Deputy President Paul Mashatile has told the National Assembly talks have already begun.
To fill the funding gap left by US President Donald Trump's decision to cut aid to fund HIV programmes, the government is looking towards the National Lotteries Commission and the private sector.
Deputy President Paul Mashatile told the National Assembly on Thursday there were moves to fill the health gaps in the country.
He was answering questions from MPs on a range of issues affecting the country.
'Based on the analysis of the extent of the impact of the reduced financial support, a team led by the director-general of health is already in talks with National Treasury to discuss funding options. In addition, the South African National Aids Council (SANAC) has approached the National Lotteries Commission and the SANAC Private Sector Forum to garner further funding support.
'The National Lotteries Commission has submitted a funding application for what they call the Close the Gap HIV treatment campaign and end TB campaign, which is being considered by its discretionary emergency funding. We are hopeful that all these resource mobilisation efforts will yield positive results as we cannot afford to have service delivery gaps in relation to health programmes, particularly those focusing on HIV and TB,' Mashatile told MPs.
The South African Medical Research Council (SAMRC) and National Health Laboratory Service (NHLS) are the only entities reporting to the Ministry of Health that received funding from the United States President's Emergency Plan for Aids Relief (Pepfar).
The SAMRC was awarded a US$45.6 million grant by the United States Agency for International Development (USAID) under the BRILLIANT (Bringing Innovation to Clinical and Laboratory research to end HIV In Africa through New vaccine Technology) Consortium.
The consortium develops and tests novel HIV vaccines in Africa. The NHLS received R94 657 052 annually from Pepfar.
However, the total funding for the NHLS is R210 594 552 for the period 01 October 2024 to 30 September 2025.
Mashatile said the government was also looking at acquiring affordable drugs and medicines from other countries.
'We are concerned about these cuts, and as I said earlier that we are now looking at resource mobilisation from other quarters, our own fiscals. But just to assure you that we're not looking at our own fiscals for the first time, as I said, in fact, funding from our own fiscals on these programmes already constitutes close to 75% of the budget we spend on HIV and Aids.
Mashatile said:
It is true though that when it comes to the employment of people in the districts and clinics, a lot of the funding that was used to pay for their salaries came from Pepfar and that's where the minister is trying hard now to ensure that we can deal with that.
Despite the negativity around the funding cuts, Mashatile tried to spin a positive narrative.
He said the government was now of the view that 'perhaps the decision by the US administration to cut funding must be something that really propels us to now take urgent efforts to become self-reliant, not only as South Africa, but the continent as a whole'.
'Let's start doing things for ourselves,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
24 minutes ago
- Fox News
NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs
One of the boldest and most consistent themes in President Donald J. Trump's healthcare agenda is his determination to reduce the role and power of middlemen. From insurance companies to pharmacy benefit managers (PBMs) – and even hospitals –these intermediaries profit from the inefficiencies of our bloated health system. The result is higher costs for American families. As I explain in my new book, "Trump's Triumph: America's Greatest Comeback," the U.S. healthcare system isn't expensive just because care is costly. It's expensive because the system is complex – by design. The third-party payment structure, whether public or private, adds layers of bureaucracy. This opens the door for middlemen to offer supposed solutions that serve their own bottom lines – not patients. It's a vicious cycle: more rules lead to more middlemen, which lead to even more rules, red tape, and rising costs. President Trump understood this – and he took action. In his first term, he issued a groundbreaking executive order on price transparency. For the first time, hospitals were required to disclose the real cost of procedures, enabling patients to compare prices before receiving care. While the Biden administration weakened enforcement, Trump doubled down in his second term with an even stronger push for what he called "radical transparency." Radical transparency is the antidote to healthcare's worst inefficiencies. When patients and employers can see wide price differences for the same procedures – even within the same hospital system – the games played behind the scenes get exposed. These inflated prices often have little to do with quality and everything to do with how well insurers negotiate – or how many middlemen take a cut. The same is true for prescription drugs. PBMs – giant corporations that control which drugs are covered and at what cost – use their market power to inflate prices. Three PBMs control 80 percent of the market. They're often subsidiaries of major insurers, forming vertically integrated monopolies. New data from the Pacific Research Institute shows that most PBMs skim more money off high-cost prescriptions than European countries charge. It's no wonder Americans are paying more. Hospitals play a role as well. Many exploit a well-intentioned federal program known as 340B, which allows them to purchase drugs at steep discounts. Instead of passing the savings to patients, they bill insurers full price and pocket the difference. The program was meant to expand care for low-income patients, but there's little oversight to ensure this happens. President Trump's recent executive order on drug pricing targets this broken system. By creating a pathway for manufacturers to sell directly to patients, health plans, pharmacies, and clinics – without the markup – he's offering a way to bypass the middlemen. This isn't theory – it's already working. When insulin makers launched direct-to-consumer programs, they sold the same drug at one-fourth the price patients were paying through insurance – while still making a profit. That's the power of real market competition – without a single government price control. This stands in sharp contrast to the Left's top-down vision. Whether it's price controls, centralized purchasing, or government-run insurance, the left's answer is always more bureaucracy. But more bureaucracy means more complexity – and more room for middlemen to thrive. Perhaps the most visionary part of President Trump's health care agenda is his call to Make America Healthy Again. For decades, we've operated a "sick care" system focused on treating illness after it strikes. Trump's approach is different. It emphasizes prevention, lifestyle, and personal responsibility – turning Americans from passive recipients into active participants in their own health. In this model, the government's role isn't to run the system but to create an environment in which patients and doctors can lead – with access to better tools, more transparency, and useful information. That means clearer labeling for ultra-processed foods, ensuring gold standard scientific data free of conflicts of interest, and addressing environmental factors that contribute to chronic disease. These kinds of structural reforms empower people to make informed choices and live healthier lives – without mandates or micromanagement. It's a model that eliminates the ultimate middleman: the system itself. President Trump's leadership has laid the groundwork for a transparent, patient-centered, free-market healthcare system. But the job isn't done. Congress should join him in continuing this fight – not just to lower costs, but to restore power to the American people. America deserves a healthcare system that benefits Americans – not industry middlemen.


Washington Post
27 minutes ago
- Washington Post
Top CDC covid vaccine adviser quits after RFK Jr. ended recommendations
A top coronavirus vaccine adviser at the Centers for Disease Control and Prevention has resigned, citing concerns that she could no longer help vulnerable people after federal health officials rescinded long-standing recommendations to immunize children and pregnant women. Lakshmi Panagiotakopoulos said in an email to colleagues Tuesday that she made a 'personal decision' to quit the CDC after 12 years.

Wall Street Journal
42 minutes ago
- Wall Street Journal
Republican Megabill Would Make 11 Million People Uninsured, New Estimates Show
WASHINGTON—Passing the GOP's 'One Big Beautiful Bill' in its current form would push about 11 million people out of Medicaid or other forms of health coverage, leaving them uninsured by 2034, the nonpartisan Congressional Budget Office said Wednesday. Here's what to know: